Other multitargeted kinase inhibitors used to inhibit the PI3KCA/AKT/mechanistic target of the rapamycin kinase (MTOR) pathway in MTC are vandenitib and cabozantinib. This evidence concerns the gene MTOR and medullary thyroid gland carcinoma.